genitourinary oncology update 2021
TRANSCRIPT
![Page 1: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/1.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 1
Genitourinary Oncology Update 2021
Matthew Milowsky MDApril 28, 2021
1
Disclosures• Employment - none
• Leadership - none
• Stock and Other Ownership Interests – none
• Honoraria - none
• Consulting or Advisory Role – none
• Speaker’s Bureau - none
• Research Funding (institution)– Merck, Roche/Genentech, Bristol-Myers Squibb, Seagen, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, Mirati Therapeutics, Constellation Pharmaceuticals, Syndax, Incyte, Amgen, Regeneron, Arvinas, Pfizer, Johnson & Johnson/Janssen
• Patents, Royalties, Other Intellectual Property – none
• Expert Testimony - none
• Travel, Accommodations, Expenses - none
• Other Relationship - none
2
2021 GU Cancers Symposium Highlights
Lu-177-PSMA therapy for prostate cancer
Enfortumab Vedotin for advanced urothelial cancer
and more…
ADC, radioligand therapy, adjuvant immunotherapy,
Adjuvant Nivolumab in MIUC
3
![Page 2: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/2.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 2
Prostate Cancer Update
1. TheraP (ANZUP 1603) – Lu-177-PSMA in mCRPC2. ACIS – Apa/Abi vs. Abi in mCRPC
4
TheraP (ANZUP 1603)
5
177-Lu-PSMA-617
6
![Page 3: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/3.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 3
TheraP (ANZUP 1603)
7
TheraP (ANZUP 1603)
8
TheraP (ANZUP 1603)
9
![Page 4: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/4.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 4
TheraP (ANZUP 1603)
10
TheraP (ANZUP 1603)
11
TheraP (ANZUP 1603)
12
![Page 5: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/5.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 5
Press Release (3/23/2021): Phase III VISION study
https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer
Likely practice changing (awaiting data)
13
ACIS
14
ACIS
15
![Page 6: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/6.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 6
ACIS
16
ACIS
17
ACIS
No OS benefit seen
18
![Page 7: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/7.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 7
ACIS
19
ACIS – Not practice changing without improvement in OS
20
Bladder Cancer Update
1. EV-301– EV vs. Chemotherapy in mUC (previously treated)2. EV-201 – EV in cisplatin-unfit mUC (prior IO)3. CheckMate 274 – adjuvant Nivolumab in high-risk MIUC
21
![Page 8: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/8.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 8
EV-301
22
Enfortumab Vedotin
23
EV-301
24
![Page 9: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/9.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 9
EV-301
25
EV-301
26
EV-301
27
![Page 10: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/10.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 10
EV-301
28
EV-301
29
EV-301
30
![Page 11: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/11.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 11
EV-301 – Practice changing
31
EV-201
32
EV-201
33
![Page 12: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/12.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 12
EV-201
34
EV-201
35
EV-201
36
![Page 13: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/13.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 13
EV-201
37
EV-201
38
EV-201
39
![Page 14: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/14.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 14
EV-201 – Promising but not practice changing at this time
40
CheckMate 274
41
CheckMate 274
42
![Page 15: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/15.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 15
CheckMate 274
43
CheckMate 274
44
CheckMate 274
45
![Page 16: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/16.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 16
CheckMate 274
46
CheckMate 274
47
CheckMate 274
48
![Page 17: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/17.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 17
CheckMate 274 – Potential to be practice changing…
49
IMvigor 010
50
IMvigor 010
51
![Page 18: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/18.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 18
IMvigor 010
52
ALLIANCE A031501: Phase III randomized “Adjuvant study of peMBrolizumAb in muScle invaSive and locAlly aDvanced urOthelial carcinoma” (AMBASSADOR) versus observation
Pembrolizumab200mg q3W
1 year
Observation
RANDOMIZE
Eligibility
§ M IBC or UTUC
Radical cystectomy nephrectomy, nephroureterectomy or ureterectomy ≥4 but ≤ 16 weeks
§Post-neoadjuvant chemotherapy and ≥ pT2 and/or N+
OR§cisplatin-ineligible and ≥ pT3 or pN+/+margins
OR§decline adjuvant chemo and ≥ pT3 or pN+/+ margins
DISEASE
FREE
SURVIVAL
Stratify§ PDL1 +/-
§ Neoadjuvantchemotherapyyes/no
§ Pathologic stage: pT2/3/4aN0 vs pT4bNx orN1-3 vs +microscopic invasive margins
1:1
OVERALL
SURVIVAL
N=739
Co-primary
Presented by Andrea B. Apolo
Central PD-L1 testing
Pre-registrationRegistration
53
Kidney Cancer Update
1. CLEAR – Len/Pem in advanced ccRCC2. SWOG 1500 – Cabo in pRCC
54
![Page 19: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/19.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 19
CLEAR
55
CLEAR
56
CLEAR
57
![Page 20: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/20.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 20
CLEAR
58
CLEAR
59
CLEAR
60
![Page 21: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/21.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 21
CLEAR
61
CLEAR
62
CLEAR
63
![Page 22: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/22.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 22
CLEAR – Practice changing as another IO/VEGFR TKI combo
64
First-line options for metastatic ccRCC
c/o Dr. Tracy Rose, UNC
65
SWOG 1500
66
![Page 23: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/23.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 23
SWOG 1500
67
SWOG 1500
68
SWOG 1500
69
![Page 24: Genitourinary Oncology Update 2021](https://reader036.vdocument.in/reader036/viewer/2022072502/62dd0ae203af615ccd002563/html5/thumbnails/24.jpg)
UNC Lineberger Cancer Network Presented on April 28, 2021
For Educational Use Only 24
SWOG 1500
70
SWOG 1500 – Practice changing as new standard for pRCC
71
2021 GU Cancers Symposium Highlights
• Thank you for your attention.
72